Brain Efflux Index To Investigate the Influence of Active Efflux on Brain Distribution of Pemetrexed and Methotrexate
暂无分享,去创建一个
[1] Li Li,et al. pH-Dependent Transport of Pemetrexed by Breast Cancer Resistance Protein , 2011, Drug Metabolism and Disposition.
[2] P. Wen,et al. Survival among patients with primary central nervous system lymphoma, 1973–2004 , 2011, Journal of Neuro-Oncology.
[3] R. Kim,et al. Blood−brain barrier transporters and response to CNS-active drugs , 2009, European Journal of Clinical Pharmacology.
[4] Y. Sugiyama,et al. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs , 2009, Expert opinion on drug metabolism & toxicology.
[5] O. van Tellingen,et al. Functionally Overlapping Roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the Elimination of Methotrexate and Its Main Toxic Metabolite 7-Hydroxymethotrexate In vivo , 2009, Clinical Cancer Research.
[6] T. Batchelor,et al. LONG-TERM OUTCOME IN PCNSL PATIENTS TREATED WITH HIGH-DOSE METHOTREXATE AND DEFERRED RADIATION , 2008, Neurology.
[7] Thomas J. Raub,et al. Roles of P-Glycoprotein, Bcrp, and Mrp2 in Biliary Excretion of Spiramycin in Mice , 2007, Antimicrobial Agents and Chemotherapy.
[8] H. Pospisil,et al. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression , 2007, Investigational New Drugs.
[9] T. Fukami,et al. P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood–brain barrier , 2007, Journal of drug targeting.
[10] F. Russel,et al. Interaction of Nonsteroidal Anti-Inflammatory Drugs with Multidrug Resistance Protein (MRP) 2/ABCC2- and MRP4/ABCC4-Mediated Methotrexate Transport , 2007, Journal of Pharmacology and Experimental Therapeutics.
[11] T. Terasaki,et al. Functional characterization of the brain-to-blood efflux clearance of human amyloid-β peptide (1–40) across the rat blood–brain barrier , 2006, Neuroscience Research.
[12] J. Schellens,et al. Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies Using Mrp2 (Abcc2) Knockout Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.
[13] L. Recht,et al. Optimizing therapy for patients with brain metastases. , 2006, Seminars in oncology.
[14] W. Elmquist,et al. Distribution of the Novel Antifolate Pemetrexed to the Brain , 2005, Journal of Pharmacology and Experimental Therapeutics.
[15] P. Wielinga,et al. Mrp4 Confers Resistance to Topotecan and Protects the Brain from Chemotherapy , 2004, Molecular and Cellular Biology.
[16] Tetsuya Terasaki,et al. Organic anion transporter 3 is involved in the brain‐to‐blood efflux transport of thiopurine nucleobase analogs , 2004, Journal of neurochemistry.
[17] S. Cole,et al. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. , 2004, Current drug metabolism.
[18] E. L. Volk,et al. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. , 2003, Cancer research.
[19] P. L. Golden,et al. Blood-brain barrier efflux transport. , 2003, Journal of pharmaceutical sciences.
[20] H. Kusuhara,et al. Contribution of Organic Anion Transporter 3 (Slc22a8) to the Elimination of p-Aminohippuric Acid and Benzylpenicillin across the Blood-Brain Barrier , 2003, Journal of Pharmacology and Experimental Therapeutics.
[21] H. Takanaga,et al. Rat Organic Anion Transporter 3 (rOAT3) is Responsible for Brain-to-Blood Efflux of Homovanillic Acid at the Abluminal Membrane of Brain Capillary Endothelial Cells , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[22] H. Takanaga,et al. Role of blood–brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain , 2002, Journal of neurochemistry.
[23] M. Kuwano,et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. , 2002, Cancer research.
[24] Y. Sugiyama,et al. In vivo evidence for brain-to-blood efflux transport of valproic acid across the blood-brain barrier. , 2002, Microvascular research.
[25] T. Abe,et al. Characterization of the Efflux Transport of 17β-Estradiol-d-17β-glucuronide from the Brain across the Blood-Brain Barrier , 2001 .
[26] Q. Smith,et al. Characterization of the blood–brain barrier choline transporter using the in situ rat brain perfusion technique , 2001, Journal of neurochemistry.
[27] J. Drewe,et al. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. , 2000, Molecular pharmacology.
[28] R. Evers,et al. Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. , 2000, Molecular pharmacology.
[29] H. Kusuhara,et al. Molecular Cloning and Characterization of a New Multispecific Organic Anion Transporter from Rat Brain* , 1999, The Journal of Biological Chemistry.
[30] H. Kusuhara,et al. P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier. , 1997, The Journal of pharmacology and experimental therapeutics.
[31] B A Telfer,et al. Tissue water content in rats measured by desiccation. , 1997, Journal of pharmacological and toxicological methods.
[32] Y. Sugiyama,et al. In vivo evidence for carrier-mediated efflux transport of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. , 1997, The Journal of pharmacology and experimental therapeutics.
[33] Y. Sugiyama,et al. Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. , 1996, The Journal of pharmacology and experimental therapeutics.
[34] H. Kusuhara,et al. Active efflux across the blood-brain barrier: Role of the solute carrier family , 2011, NeuroRX.
[35] J. Olson,et al. Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study , 2008, Journal of Neuro-Oncology.
[36] A. Klein-Szanto,et al. Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage. , 2007, Cancer research.
[37] C. Waters,et al. Pharmacokinetic Considerations in the Treatment of CNS Tumours , 2006, Clinical pharmacokinetics.
[38] H. Kusuhara,et al. Brain efflux index method. Characterization of efflux transport across the blood-brain barrier. , 2003, Methods in molecular medicine.
[39] H. Kusuhara,et al. Brain Efflux Index Method , 2003 .
[40] W. Pardridge. Crossing the blood-brain barrier: are we getting it right? , 2001, Drug discovery today.
[41] T. Abe,et al. Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. , 2001, The Journal of pharmacology and experimental therapeutics.
[42] W. Pardridge. Blood-brain barrier biology and methodology. , 1999, Journal of neurovirology.
[43] J. Gallo,et al. In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-Bearing rats , 1996, Cancer Chemotherapy and Pharmacology.